Synthesis-driven reverse metabolomics reveals 3-hydroxy N -acyl amides as gut microbial molecules

Abstract 3-hydroxy N-acyl amides are bioactive lipids with reported anti-obesity and glucose-regulating effects, yet they are rarely detected in untargeted metabolomics studies because they are largely absent from existing spectral reference libraries. To address this gap, we synthesized an MS2 spectral resource comprising 436 structurally diverse 3-hydroxy N-acyl amides, spanning 3- to 18-carbon chains with a wide range of amine headgroups such as ornithine, valine, and dopamine. Using a synthesis-driven reverse metabolomics approach, we found 161,626 spectral matches across 54,744 publicly available files in untargeted metabolomics datasets revealing widespread occurrences in biological samples, including human-derived specimens. Of these molecules detected through MS2 spectral matching, 334 represent newly reported biological entities. We further confirmed their presence in human saliva, stool, and skin using retention time and ion mobility measurements. Frequent detection in microbial datasets and validation in communities of human-derived gut bacteria support microbial production. Several metabolites also showed altered abundance in individuals with diabetes mellitus, showing that this lipid class is modulated in human metabolic disease. Together, these findings establish 3-hydroxy N-acyl amides as a distinct and biologically relevant lipid class, and the accompanying MS2 spectral resource will enable their broader recognition and study in untargeted metabolomics data. Competing Interest Statement P.C.D. is a scientific advisor and holds equity in Cybele, Sirenas and bileOmix, and is a Scientific Co-founder, and advisor, received income and/or holds equity in Ometa, Arome, and Enveda with prior approval by UC-San Diego.